UNLABELLED: Little is known about the potential involvement of the oncoprotein gankyrin in human oral cancer progression. In this study, the levels of gankyrin mRNA and protein expression were assessed in human oral epithelial cell lines, at-risk normal oral tissues, premalignant oral lesions, and primary oral squamous cell carcinomas (OSCCs). MATERIALS AND METHODS: Biopsies included 6 oral epithelial cell lines, 32 OSCC specimens for qRT-PCR analysis, 27 OSCC specimens and 12 premalignant oral lesions for immunohistochemical analysis. RESULTS: Gankyrin was overexpressed in all tested oral epithelial cell lines and the majority of OSCC specimens (32/32 (100%) and 21/27 (71%) at the mRNA and protein levels, respectively). Moreover, 6/12 of premalignant oral lesions overexpressed gankyrin protein. CONCLUSION: Gankyrin overexpression is a prevalent event in human oral cancer and occurs during the early stages of oral carcinogenesis, thus being a viable therapeutic or chemopreventive target in oral cancer.
UNLABELLED: Little is known about the potential involvement of the oncoprotein gankyrin in humanoral cancer progression. In this study, the levels of gankyrin mRNA and protein expression were assessed in human oral epithelial cell lines, at-risk normal oral tissues, premalignant oral lesions, and primary oral squamous cell carcinomas (OSCCs). MATERIALS AND METHODS: Biopsies included 6 oral epithelial cell lines, 32 OSCC specimens for qRT-PCR analysis, 27 OSCC specimens and 12 premalignant oral lesions for immunohistochemical analysis. RESULTS:Gankyrin was overexpressed in all tested oral epithelial cell lines and the majority of OSCC specimens (32/32 (100%) and 21/27 (71%) at the mRNA and protein levels, respectively). Moreover, 6/12 of premalignant oral lesions overexpressed gankyrin protein. CONCLUSION:Gankyrin overexpression is a prevalent event in humanoral cancer and occurs during the early stages of oral carcinogenesis, thus being a viable therapeutic or chemopreventive target in oral cancer.
Authors: Ming J Poi; Thomas J Knobloch; Marta T Sears; Lana K Uhrig; Blake M Warner; Christopher M Weghorst; Junan Li Journal: Anticancer Res Date: 2014-07 Impact factor: 2.480
Authors: Junan Li; Thomas J Knobloch; Ming J Poi; Zhaoxia Zhang; Andrew T Davis; Peter Muscarella; Christopher M Weghorst Journal: Mol Carcinog Date: 2012-10-12 Impact factor: 4.784
Authors: Ming J Poi; Thomas J Knobloch; Chunhua Yuan; Ming-Daw Tsai; Christopher M Weghorst; Junan Li Journal: Biochem Biophys Res Commun Date: 2013-05-29 Impact factor: 3.575
Authors: Ming J Poi; Thomas J Knobloch; Marta T Sears; Blake M Warner; Lana K Uhrig; Christopher M Weghorst; Junan Li Journal: Mol Carcinog Date: 2013-12-02 Impact factor: 4.784